Legislation roundup: Pharma monopoly and export, and data interface security risk monitoring

August 16, 2024 | BY

Susan Mok

SAMR prohibits monopoly agreements that fix or modify pharmaceutical prices. Export pharmaceuticals commissioned for production from a foreign pharmaceutical manufacturer may not be sold and used in the PRC. Guidelines are provided for the methods of monitoring data interface security risks.

Share:

Pharmaceuticals

State Administration for Market Regulation, Anti-Monopoly Guidelines for the Pharmaceuticals Sector (Draft for Comments)

国家市场监督管理总局关于药品领域的反垄断指南 (征求意见稿)

Fixing or Modifying Pharmaceutical Prices

Pharmaceutical business operators that are competitors are forbidden from entering